Guides, research, and insights from Research
14 articlesKisspeptin-10 restarts LH pulsing. BPC-157 protects organs. NAD+ supports cellular recovery. DSIP fixes post-cycle sleep. The peptide-based PCT protocol.
CJC-1295/Ipa for GH, Tesamorelin for visceral fat, MOTS-C for metabolism, BPC-157 for joints. The phased peptide protocol for men 40+.
BPC-157 injection protocol for rotator cuff injuries: local vs systemic, dosing, the Wolverine Stack for shoulders, and when to pair with TB-500.
BPC-157 for grappler joints, TB-500 for systemic recovery, Semax for neuroprotection, DSIP for recovery sleep. WADA considerations for competitors.
Why the research community combines these two peptides, what the theoretical basis is, and what the evidence actually supports about synergistic tissue repair.
Thymosin Beta-4 fragment (TB-500) has been studied for tissue repair and wound healing. Here's what the research actually supports — and where it falls short.
In February 2026, the HHS Secretary announced 14 peptides would be 'unleashed.' Three months later, here's what's actually changed, what hasn&am
Third-party testing, certificates of analysis, purity thresholds, and red flags. A practical framework for evaluating research peptide vendors.
A clear-eyed overview of where peptides stand legally in the United States — compounding eligibility, 'research use only' designations, DEA scheduling, and what
KPV is a tripeptide fragment of alpha-MSH with documented anti-inflammatory properties in preclinical models. Here's what the research shows — and what the July 2026 PCA
The two most widely used growth hormone-releasing peptides in the research community — how they work, what the evidence shows, and why the PCAC previously voted against them.
GHK-Cu is one of the most extensively studied peptides in regenerative medicine — with decades of research, topical FDA-cleared products, and ongoing review for injectable compou
The FDA's Pharmacy Compounding Advisory Committee meets July 23-24, 2026 to review BPC-157, TB-500, KPV, and MOTs-C. Here's what's at stake and what to e
Two decades of rodent data, a handful of early human studies, and a regulatory landscape in flux. Here's the evidence — and the gaps — for the most-discussed peptide i
No articles found matching your search.